915006-52-9

Basic information

• Product Name: 5-Amino-2-bromo-6-iodopyridine
• Synonyms: 5-Amino-2-bromo-6-iodopyridine;3-AMino-6-broMo-2-iodopyridine;6-BroMo-2-iodo-pyridin-3-ylaMine;3-PyridinaMine, 6-broMo-2-iodo-;6-bromo-2-iodopyridin-3-amine
• CAS NO: 915006-52-9
• Molecular Formula: C₅H₄BrIN₂
• Molecular Weight: 298.905
• Mol File: 915006-52-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 362.5±42.0 °C(Predicted)
• Appearance: /
• Density: 2.426±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -0.19±0.10(Predicted)
• CAS DataBase Reference: 5-Amino-2-bromo-6-iodopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-2-bromo-6-iodopyridine(915006-52-9)
• EPA Substance Registry System: 5-Amino-2-bromo-6-iodopyridine(915006-52-9)

Safety Data

• Hazardous Substances Data: 915006-52-9(Hazardous Substances Data)

Usage

General Description

5-Amino-2-bromo-6-iodopyridine is a chemical compound with the molecular formula C5H3BrIN2. It is a pyridine derivative with a bromo and an iodo substituent at positions 2 and 6, and an amino group at position 5. 5-Amino-2-bromo-6-iodopyridine is utilized in synthetic organic chemistry as a building block for the construction of more complex molecules. It is also used in the pharmaceutical industry for the synthesis of various drugs and biologically active compounds. 5-Amino-2-bromo-6-iodopyridine is a versatile and valuable chemical intermediate with a range of applications in research and industry.

Upstream product

• 13534-97-9 6-bromopyridine-3-amine 

Downstream Products

• 800401-52-9 5-bromo-1H-pyrrolo[3,2-b]pyridine-2-carboxylic acid 
• 915006-53-0 6-bromo-2-(4,4-dimethyl-cyclohex-1-enyl)-pyridin-3-ylamine 

Relevant articles and documents

PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS

Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity

Replacement of the pyridine core of antimalarial 3,5-diaryl-2- aminopyridines led to the identification of a novel series of pyrazine analogues with potent oral antimalarial activity. However, other changes to the pyridine core and replacement or substitution of the 2-amino group led to loss of antimalarial activity. The 3,5-diaryl-2-aminopyrazine series showed impressive in vitro antiplasmodial activity against the K1 (multidrug resistant) and NF54 (sensitive) strains of Plasmodium falciparum in the nanomolar IC50 range of 6-94 nM while also demonstrating good in vitro metabolic stability in human liver microsomes. In the Plasmodium berghei mouse model, this series generally exhibited good efficacy at low oral doses. One of the frontrunner compounds, 4, displayed potent in vitro antiplasmodial activity with IC 50 values of 8.4 and 10 nM against the K1 and NF54 strains, respectively. When evaluated in P. berghei-infected mice, compound 4 was completely curative at an oral dose of 4 × 10 mg/kg.

INHIBITORS OF C-FMS KINASE

The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.